clinical trial · NCT07365462
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
Tardive DyskinesiaNBI-1065890Placebo
brief summary
The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
started
Jan 23, 2026
primary completion
Feb 1, 2027
completion
Mar 1, 2027
last updated
Apr 24, 2026
official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol